Abstract
This study examines the safety, tolerability, and efficacy of anticancer drugs in the treatment of multiple myeloma, a malignancy of plasma cells characterized by overproduction of monoclonal proteins that damage bones and organs. The disease remains largely incurable despite advances in treatment, necessitating ongoing evaluation of therapeutic approaches. This review focuses on the role of key medications like bortezomib, lenalidomide, and daratumumab, highlighting their mechanisms, clinical efficacy, and associated adverse effects. Bortezomib, a proteasome inhibitor, has shown significant efficacy in both newly diagnosed and relapsed/refractory cases, particularly in combination regimens. However, it is associated with adverse effects such as peripheral neuropathy and hematologic and gastrointestinal toxicities, which require careful management. Strategies such as optimized dosing and subcutaneous administration have improved its safety profile. Future directions include enhancing therapeutic outcomes through personalized medicine, combination regimens, and mitigating resistance. This research underscores the critical need for tailored treatment strategies to improve patient survival and quality of life in multiple myeloma. Keywords: BiPN – Bortezomib-induced Peripheral Neuropathy, RRMM –Relapsed and Refractory Multiple Myeloma, NDMM –Newly Diagnosed Multiple Myeloma, PN –Peripheral Neuropathy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call